Research ArticleCancer

ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma

See allHide authors and affiliations

Science Translational Medicine  20 Jan 2021:
Vol. 13, Issue 577, eabc0170
DOI: 10.1126/scitranslmed.abc0170

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

An ACE2 in the hole

Clear cell renal cell carcinoma (ccRCC) is a form of kidney cancer commonly treated with agents targeting vascular endothelial growth factor (VEGF) signaling; however, resistance develops. Cotreatment with inhibitors of angiotensin signaling can improve survival, so Khanna et al. focused on the role of angiotensin converting enzyme 2 (ACE2), a natural antagonist of classical angiotensin signaling. Higher expression of ACE2 correlated with better survival in patients with ccRCC, and overexpression of ACE2 inhibited tumor colony formation. Combining angiotensin-(1-7), a cleavage product of ACE2, with VEGF inhibition provided greater antitumor effects than VEGF inhibition alone, suggesting a potential therapy for ccRCC.

View Full Text

Stay Connected to Science Translational Medicine